Abstract 3951
Background
Neutrophil-lymphocyte ratio (NLR) is a predictive factor of survival in cancer, probably as a biomarker of systemic inflammation, but with limited evidence in neuroendocrine neoplasms (NENs). NENs are a very heterogeneous disease with a large range of survival from few months to many years. Stage, grade and primary tumor location are known prognostic factors, but still limited. New prognostic biomarkers are needed. The aim of this study is to evaluate the association between NRL and survival (OS) in neuroendocrine neoplasms.
Methods
Data from patients diagnosed with extra-pulmonary neuroendocrine neoplasms (Grade 1 to 3) from a Portuguese tertiary cancer center were reviewed retrospectively (January 00 - March 19). NLR was calculated at diagnosis as the ratio between neutrophils and lymphocytes.
Results
In our cohort, 116 patients were identified (52% male; median age 62yo (IQR 33-80) with neuroendocrine neoplasms: 76 gastroenteropancreatic (GEP), 32 unknown primary (UP) and 8 from other primary tumor location. 54 patients were G1/G2 and 51 patients were G3/NEC. 5year OS was different according to grade [79% (IC95% 68-91%) for G1/G2 tumors and 16% (IC95% 7-35%) for G3/NEC (p < 0.001)] and to primary tumor location [62% (95%CI 51-76%) for GEP and 15% (95%CI 6-34%) for UP (p < 0.001)]. NLR analysis started by determination of NLR median in this cohort: 2.526 (IQR 1.690-3.681). Patients were then divided in two groups: low NLR (< 2.526) and high NLR (≥2.526). 5year OS according to NLR was significantly different: 58% (IC95% 46-73%) for low NLR and 33% (ICD95% 22-49%) for high NLR (p = 0.038). After stratification by grade and primary tumor location, influence of NLR categories remains, patients with high NLR had a poor OS comparing to patients with low NLR (HR = 1.87, 95%CI 1.00-3.49, p = 0.05). A non-categorical analysis of NLR, stratified by grade and primary tumor location, showed that the risk of death increases 17% by each 1 unit rise in NLR (HR = 1.17, 95%CI 1.08-1.27, p = 0.0002).
Conclusions
Our study showed that NRL is an independent prognostic factor in survival in neuroendocrine neoplasms. Further studies are needed to evaluate the prognostic value of NLR as well as to evaluate its ability to predict response to different therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5629 - Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumor infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion
Presenter: Luca Campedel
Session: Poster Display session 2
Resources:
Abstract
5792 - A novel PET parameter for cancer stem cell metabolism: early prediction of chemosensitivity to neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Chanwoo Kim
Session: Poster Display session 2
Resources:
Abstract
3728 - Using nodal ratio to predict recurrence in patients with 4 or more positive lymph nodes early stage breast cancer
Presenter: Besma Graja
Session: Poster Display session 2
Resources:
Abstract
3395 - Re-sentinel node biopsy for local recurrence after breast-conserving surgery
Presenter: Yuka Matsubara
Session: Poster Display session 2
Resources:
Abstract
4302 - Assessment of prognostic and therapeutic factors in men with breast cancer
Presenter: Daniel Herrero Rivera
Session: Poster Display session 2
Resources:
Abstract
4263 - Genomic Profiling of Chinese Breast Cancer Patients
Presenter: Zhonghua Tao
Session: Poster Display session 2
Resources:
Abstract
2406 - Genome copy number alteration burden represents predictor of response in long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
Presenter: Naomi Walsh
Session: Poster Display session 2
Resources:
Abstract
2575 - Next-generation DNA Sequencing (NGS) Results for Tumors From Phase 2 ABRAZO Study of Talazoparib After Platinum or Cytotoxic Non-Platinum Regimens in Patients (pts) With Advanced Breast Cancer (ABC) and Germline BRCA1/2 (gBRCA) Mutations
Presenter: Nicholas C. Turner
Session: Poster Display session 2
Resources:
Abstract
4499 - FGFR1 and CCND1 gene amplifications are associated with breast cancer resistance to aromatase inhibitors
Presenter: Evgeny Imyanitov
Session: Poster Display session 2
Resources:
Abstract
4110 - Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe Experience
Presenter: Sercan Aksoy
Session: Poster Display session 2
Resources:
Abstract